199 related articles for article (PubMed ID: 23245937)
1. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
3. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
4. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.
Armstrong PC; Leadbeater PD; Chan MV; Kirkby NS; Jakubowski JA; Mitchell JA; Warner TD
J Thromb Haemost; 2011 Mar; 9(3):552-61. PubMed ID: 21143373
[TBL] [Abstract][Full Text] [Related]
5. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
6. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.
Fox SC; May JA; Johnson A; Hermann D; Strieter D; Hartman D; Heptinstall S
Platelets; 2013; 24(5):392-400. PubMed ID: 22866894
[TBL] [Abstract][Full Text] [Related]
7. Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
Labarthe B; Babin J; Bryckaert M; Théroux P; Bonnefoy A
Br J Pharmacol; 2012 May; 166(1):221-31. PubMed ID: 21950486
[TBL] [Abstract][Full Text] [Related]
8. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S
Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084
[TBL] [Abstract][Full Text] [Related]
9. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
10. Detection of platelet sensitivity to inhibitors of COX-1, P2Y₁, and P2Y₁₂ using a whole blood microfluidic flow assay.
Li R; Diamond SL
Thromb Res; 2014 Feb; 133(2):203-10. PubMed ID: 24365044
[TBL] [Abstract][Full Text] [Related]
11. Platelet activation and inhibition in sickle cell disease (pains) study.
Frelinger AL; Jakubowski JA; Brooks JK; Carmichael SL; Berny-Lang MA; Barnard MR; Heeney MM; Michelson AD
Platelets; 2014; 25(1):27-35. PubMed ID: 23469943
[TBL] [Abstract][Full Text] [Related]
12. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.
Warner TD; Nylander S; Whatling C
Br J Clin Pharmacol; 2011 Oct; 72(4):619-33. PubMed ID: 21320154
[TBL] [Abstract][Full Text] [Related]
13. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
[TBL] [Abstract][Full Text] [Related]
15. Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.
Högberg C; Gidlöf O; Deflorian F; Jacobson KA; Abdelrahman A; Müller CE; Olde B; Erlinge D
Thromb Haemost; 2012 Jul; 108(1):119-32. PubMed ID: 22628078
[TBL] [Abstract][Full Text] [Related]
16. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
17. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors.
Jin J; Quinton TM; Zhang J; Rittenhouse SE; Kunapuli SP
Blood; 2002 Jan; 99(1):193-8. PubMed ID: 11756171
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.
Cattaneo M; Lecchi A
J Thromb Haemost; 2007 Mar; 5(3):577-82. PubMed ID: 17155953
[TBL] [Abstract][Full Text] [Related]
19. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
20. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]